International prevalence of chemical sensitivity, co-prevalences with asthma and autism, and effects from fragranced consumer products

Anne Steinemann¹²

Received: 12 December 2018 / Accepted: 23 January 2019 / Published online: 12 February 2019
© The Author(s) 2019

Abstract
Chemical sensitivity is a medical condition characterized by adverse health effects from exposure to common chemical pollutants and products. This study investigated the prevalence of chemical sensitivity in four countries—the United States (US), Australia (AU), Sweden (SE), and the United Kingdom (UK). In addition, it investigated the co-prevalence of chemical sensitivity with medically diagnosed multiple chemical sensitivities (MCS), fragrance sensitivity (health problems from fragranced products), asthma/asthma-like conditions, and autism/autism spectrum disorders (ASDs). Using nationally representative population samples in each country, data were collected in June 2016 and June 2017 through on-line cross-sectional surveys of adults (n = 4435). Results found that, across the four countries, 19.9% of the population report chemical sensitivity, 7.4% report medically diagnosed MCS, 21.2% report either or both, and 32.2% report fragrance sensitivity. In addition, 26.0% of the population report asthma/asthma-like conditions, of which 42.6% report chemical sensitivity and 57.8% fragrance sensitivity. Also, 4.5% of the population report autism/ASDs, of which 60.6% report chemical sensitivity and 75.8% fragrance sensitivity. Among individuals with chemical sensitivity, 55.4% also report asthma/asthma-like conditions, 13.5% autism/ASDs, and 82.0% fragrance sensitivity. Although the prevalence of chemical sensitivity across the countries is statistically different, its co-prevalences with other conditions are statistically similar. Results also found that, for 44.1% of individuals with chemical sensitivity, the severity of health effects from fragranced products can be potentially disabling. Further, 28.6% of those with chemical sensitivity have lost workdays or a job, in the past year, due to exposure to fragranced products in the workplace. Results indicate that chemical sensitivity is widespread across the four countries, affecting over 61 million people, that vulnerable individuals such as those with asthma and autism are especially affected, and that fragranced consumer products can contribute to the adverse health, economic, and societal effects.

Keywords Chemical sensitivity · Multiple chemical sensitivities · MCS · Fragrance · Asthma · Autism

Introduction

Chemical pollutants have been associated with deleterious effects on the environment and human health. A constellation of adverse health effects have been associated with chemical sensitivity, a medical condition that is typically initiated and triggered by exposure to common petrochemical products and pollutants, such as pesticides, building materials, solvents, new carpet and paint, and consumer products (Ashford and Miller 1998; Caress and Steinemann 2003; Steinemann 2018c). Health effects associated with these chemical exposures include headaches, dizziness, seizures, heart arrhythmia, gastrointestinal problems, mucosal symptoms, breathing difficulties, and asthma attacks (Steinemann 2018c, d, f, 2019; Ashford and Miller 1998). Notably, these volatile chemical products that are associated with adverse health effects are also primary sources of indoor and outdoor air pollutants (McDonald et al. 2018; Ott et al. 2007).

Among these sources of exposure, fragranced consumer products can be a primary trigger of health problems.
Fragranced consumer products (or fragranced products)—chemically formulated products with the addition of a fragrance or a scent (Steinemann 2015)—include a range of items such as air fresheners, laundry products, cleaning supplies, personal care products, colognes, and household items. An individual “fragrance” in a product is typically a complex mixture of several dozen to several hundred compounds, many derived from petrochemicals (Sell 2006). Fragranced products have been associated with adverse health and societal effects in the general population (Caress and Steinemann 2009b; Steinemann 2016, 2017, 2018a, b), and especially vulnerable sub-populations such as those with asthma (Weinberg et al. 2017, Steinemann et al. 2018, Steinemann 2018g), autism (Steinemann 2018e), and chemical sensitivity (Caress and Steinemann 2005, 2009a, b; Steinemann 2018c, d, f, 2019).

Relatively little is known about the prevalence of chemical sensitivity at the national or international levels, or its co-prevalence with other health conditions. One challenge is the lack of an internationally consistent definition and diagnostic criteria (e.g., Lacour et al. 2005; MCS 1999; De Luca et al. 2011; Genuis 2010). Another challenge is that different studies often use different terms and criteria for assessment. While chemical sensitivity is a common and general term, other terms include chemical intolerance (Palmquist et al. 2014; Miller 2001), toxicant-induced loss of tolerance (Miller 1997), and multiple chemical sensitivities (Ashford and Miller 1998). Further, chemically sensitive individuals may manifest the condition even though they lack a specific diagnosis. Nevertheless, prior studies have operationalized characteristics of chemical sensitivity in order to investigate the condition.

Prior national prevalence studies of chemical sensitivity in the general population include the following. In the US, two surveys, conducted 2002–2003 (n = 1057) and 2005–2006 (n = 1058), found respectively a prevalence of 11.1% and 11.6% self-reported chemical sensitivity, and 2.5% and 3.9% medically diagnosed MCS (Caress and Steinemann 2005, 2009a). Chemical sensitivity was assessed as being “allergic or unusually sensitive to everyday chemicals like those in household cleaning products, paints, perfumes, detergents, insect spray, and things like that.” In Japan, a survey in 2012 (n = 7245) estimated a prevalence of 7.5% of chemical intolerance (Azuma et al. 2015). In Denmark, a survey in 2010 (n = 2000) found a prevalence of 8.2% of chemical intolerance (Skovbjerg et al. 2012). Chemical intolerance was assessed in these two studies using the Quick Environmental Exposure and Sensitivity Inventory (QEESI) criteria (Miller and Prihoda 1999). Also in Denmark, a survey in 2006 (n = 6000) found a prevalence of 27% reporting symptoms related to inhalation of airborne chemicals such as perfume, motor vehicle exhaust, and cleaning agents (Berg et al. 2008).

This present study investigates the prevalence of chemical sensitivity across four countries, and its co-prevalences with medically diagnosed MCS, fragrance sensitivity, asthma/asthma-like conditions, and autism/ASDs. This study also examines the types of health effects associated with exposures to fragranced consumer products, and societal effects such as access to public places, lost workdays and lost jobs, and preferences for fragrance-free environments. It provides a meta-analysis and synthesis of the individual studies in each country (Steinemann 2018c, d, f, 2019), together with new statistics on the co-prevalences among the conditions, offering greater depth and breadth of findings into the pervasiveness and effects of chemical sensitivity in the general population and in vulnerable sub-populations.

**Methods**

Four national cross-sectional surveys, using the same instrument implemented in each country’s native language, were conducted of adults in the United States (US), Australia (AU), United Kingdom (UK), and Sweden (SE). Sample populations were representative of the general populations according to age, gender, and region (n = 1137, 1098, 1100, 1100; respectively; confidence limit = 95%, margin of error = 3% for all studies). Using randomized participant recruitment (SSI 2016), the surveys drew upon large web-based panels (with over 5,000,000; 200,000; 900,000; 60,000 people, respectively) held by Survey Sampling International. The survey instrument was developed and tested over a two-year period before full implementation in June 2016 (US, AU, UK) and June 2017 (SE). The survey response rate was 94%, 93%, 97%, and 92% (respectively), and all responses were anonymous. The research study received ethics approval from the University of Melbourne. Survey methods are detailed in the Electronic supplementary material (ESM-Methods).

Descriptive statistics and cross-tabulations determined percentages according to each response and sub-population; see Electronic supplementary material (ESM-Data).

Prevalence odds ratios (PORs) measured the strength of associations to determine whether one sub-population is proportionally more affected than another. Chi-squared analyses compared proportions among countries to determine whether a statistically significant difference exists. All POR and Chi-squared analyses were performed using a 95% confidence interval (CI) or a 95% confidence level, respectively.

To promote comparability, the survey replicated questions from previous studies of chemical sensitivity, MCS, asthma/asthma-like conditions, autism/ASDs, and fragrance sensitivity (Steinemann 2016, 2017, 2018a, b, c, d, e, f, g, 2019; Steinemann et al. 2018; Kreutzer et al. 1999; Caress and Steinemann 2005, 2009a, b), as follows.
For chemical sensitivity, the survey asked, “Compared to other people, do you consider yourself allergic or unusually sensitive to everyday chemicals like those in household cleaning products, paints, perfumes, detergents, insect spray and things like that?” For medically diagnosed MCS, the survey asked, “Has a doctor or health care professional ever told you that you have multiple chemical sensitivities?”

For asthma/asthma-like conditions, the survey asked, “Has a doctor or health care professional ever told you that you have asthma or an asthma-like condition?” If the respondent answered yes, the survey then asked to specify whether “asthma” or an “asthma-like condition” or both.

For autism/autism spectrum disorders (ASDs), the survey asked, “Has a doctor or health care professional ever told you that you have autism or autism spectrum disorder?” The survey then asked to specify whether autism, ASD, or both.

For fragrance sensitivity, the survey asked, “Do you experience any health problems when exposed to (fragranced product or exposure context)” If the respondent answered yes, the survey then asked about which health problems they experienced. An individual was considered to characterize fragrance sensitivity if they reported one or more types of health problems from exposure to one or more types of fragranced consumer products or exposure contexts.

Fragranced products were categorized as follows: (a) air fresheners and deodorizers (e.g., sprays, solids, oils, disks), (b) personal care products (e.g., soaps, hand sanitizer, lotions, deodorant, sunscreen, shampoos), (c) cleaning supplies (e.g., all-purpose cleaners, disinfectants, dishwashing soap), (d) laundry products (e.g., detergents, fabric softeners, dryer sheets), (e) household products (e.g., scented candles, restroom paper, trash bags, baby products), (f) fragrance (e.g., perfume, cologne, after-shave), and (g) other.

Exposure contexts included the following: air fresheners or deodorizers used within indoor environments, scented laundry products coming from a dryer vent, being in a room after it was cleaned with scented cleaning products, being near someone wearing a fragranced product, and exposure to other types of fragranced consumer products.

Health effects were categorized as follows: (a) migraine headaches, (b) asthma attacks, (c) neurological problems (e.g., dizziness, seizures, head pain, fainting, loss of coordination), (d) respiratory problems (e.g., difficulty breathing, coughing, shortness of breath), (e) skin problems (e.g., rashes, hives, red skin, tingling skin, dermatitis), (f) cognitive problems (e.g., difficulties thinking, concentrating, or remembering), (g) mucosal symptoms (e.g., watery or red eyes, nasal congestion, sneezing), (h) immune system problems (e.g., swollen lymph glands, fever, fatigue), (i) gastrointestinal problems (e.g., nausea, bloating, cramping, diarrhea), (j) cardiovascular problems (e.g., fast or irregular heartbeat, jitteriness, chest discomfort), (k) musculoskeletal problems (e.g., muscle or joint pain, cramps, weakness), and (j) other.

Societal effects included the following: ability to access restrooms, businesses, and other locations that use air fresheners or other fragranced products; loss of workdays or lost jobs due to illness from fragranced product exposure in the workplace; disabling health effects from exposure to fragranced products; and preferences for fragrance-free workplaces, healthcare facilities, and healthcare professionals.

Results

Results are presented herein for individual countries (US, AU, UK, SE, respectively) and as summaries across all four countries. Tables 1, 2, 3, 4, and 5 provide the main findings. Full results, including data and statistics for each individual country and summaries, according to questionnaire responses and sub-populations, are provided as Electronic supplementary material (ESM-Data).

Prevalence of chemical sensitivity and diagnosed MCS

Across the four countries (n = 4435), 19.9% of the general population report chemical sensitivity (25.9%, 18.9%, 16.3%, 18.5%), 7.4% report medically diagnosed MCS (12.8%, 6.5%, 6.6%, 3.6%), and 21.2% report either or both chemical sensitivity/MCS (27.5%, 19.9%, 18.0%, 19.5%) (Table 1).

Among those with chemical sensitivity, 29.2% report diagnosed MCS (42.9%, 29.0%, 30.2%, 14.7%). Among those with diagnosed MCS, 80.1% report chemical sensitivity (86.9%, 84.5%, 74.0%, 75.0%). For those with either or both conditions, 93.7% report chemical sensitivity (93.9%, 95.0%, 90.4%, 95.3%) and 33.6% report diagnosed MCS (46.3%, 32.6%, 36.9%, 18.7%) (Table 1).

For chemical sensitivity, the proportions among the four countries are statistically different (p < 0.001, Chi-square test), and for diagnosed MCS, the proportions are statistically different (p < 0.001, Chi-square test). Also, among those with chemical sensitivity who also report diagnosed MCS, the proportions are statistically different (p < 0.001). However, among those with diagnosed MCS who also report chemical sensitivity, the proportions are statistically similar (p = 0.687).

Chemical sensitivity and fragrance sensitivity

Across the countries, 32.2% of the general population report fragrance sensitivity (34.7%, 33.0%, 27.8%, 33.1%). Further, 82.0% of individuals with chemical sensitivity also report fragrance sensitivity (81.0%, 82.6%, 77.7%, 86.8%). Thus, individuals with chemical sensitivity are more likely to be fragrance sensitive than the general population (Table 1). For fragrance sensitivity, the
| Condition                        | US       | AU       | UK       | SE       | Average  |
|---------------------------------|----------|----------|----------|----------|----------|
| **Chemical sensitivity**        | 25.9%    | 18.9%    | 16.3%    | 18.5%    | 19.9%    |
| MCS                             | 42.9%    | 29.0%    | 30.2%    | 14.7%    | 29.2%    |
| Fragrance sensitivity           | 81.0%    | 82.6%    | 77.7%    | 86.8%    | 82.0%    |
| Asthma                          | 35.0%    | 32.9%    | 39.7%    | 31.4%    | 34.8%    |
| Asthma/asthma-like conditions   | 59.2%    | 56.5%    | 57.0%    | 49.0%    | 55.4%    |
| Autism                          | 8.2%     | 8.2%     | 10.1%    | 5.4%     | 8.0%     |
| Autism/ASDs                     | 13.3%    | 13.0%    | 16.2%    | 11.3%    | 13.5%    |
| **MCS**                         | 12.8%    | 6.5%     | 6.6%     | 3.6%     | 7.4%     |
| Chemical sensitivity            | 86.9%    | 84.5%    | 74.0%    | 75.0%    | 80.1%    |
| Fragrance sensitivity           | 86.2%    | 91.5%    | 89.0%    | 90.0%    | 89.2%    |
| Asthma                          | 40.0%    | 40.8%    | 49.3%    | 42.5%    | 43.2%    |
| Asthma/asthma-like conditions   | 71.0%    | 74.6%    | 74.0%    | 62.5%    | 70.5%    |
| Autism                          | 15.2%    | 28.2%    | 21.9%    | 22.5%    | 22.0%    |
| Autism/ASDs                     | 23.4%    | 39.4%    | 37.0%    | 32.5%    | 33.1%    |
| **Chemical sensitivity/MCS**    | 27.5%    | 19.9%    | 18.0%    | 19.5%    | 21.2%    |
| Chemical sensitivity            | 93.9%    | 95.0%    | 90.4%    | 95.3%    | 93.7%    |
| MCS                             | 46.3%    | 32.6%    | 36.9%    | 18.7%    | 33.6%    |
| Fragrance sensitivity           | 78.9%    | 82.1%    | 77.3%    | 86.9%    | 81.3%    |
| Asthma                          | 33.5%    | 32.1%    | 39.9%    | 30.4%    | 34.0%    |
| Asthma/asthma-like conditions   | 57.2%    | 56.4%    | 57.1%    | 47.7%    | 54.6%    |
| Autism                          | 7.7%     | 9.2%     | 9.6%     | 6.5%     | 8.3%     |
| Autism/ASDs                     | 12.8%    | 14.7%    | 16.7%    | 12.1%    | 14.1%    |
| **Fragrance sensitivity**       | 34.7%    | 33.0%    | 27.8%    | 33.1%    | 32.2%    |
| Chemical sensitivity            | 60.4%    | 47.2%    | 45.4%    | 48.6%    | 50.4%    |
| MCS                             | 31.7%    | 18.0%    | 21.2%    | 9.9%     | 20.2%    |
| Chemical sensitivity/MCS        | 62.7%    | 49.4%    | 50.0%    | 51.1%    | 53.3%    |
| Asthma                          | 35.0%    | 32.9%    | 39.7%    | 31.4%    | 34.8%    |
| Asthma/asthma-like conditions   | 59.2%    | 56.5%    | 57.0%    | 49.0%    | 55.4%    |
| Autism                          | 8.2%     | 8.2%     | 10.1%    | 5.4%     | 8.0%     |
| Autism/ASDs                     | 13.3%    | 13.0%    | 16.2%    | 11.3%    | 13.5%    |
| **Asthma/asthma-like conditions**| 26.8%    | 28.5%    | 25.3%    | 23.2%    | 26.0%    |
| Chemical sensitivity            | 57.0%    | 37.4%    | 36.7%    | 39.2%    | 42.6%    |
| MCS                             | 33.8%    | 16.9%    | 19.4%    | 9.8%     | 20.0%    |
| Chemical sensitivity/MCS        | 58.7%    | 39.3%    | 40.6%    | 40.0%    | 44.7%    |
| Fragrance sensitivity           | 64.3%    | 55.6%    | 54.0%    | 57.3%    | 57.8%    |
| Autism                          | 13.1%    | 10.2%    | 11.9%    | 10.2%    | 11.4%    |
| Autism/ASDs                     | 4.3%     | 3.7%     | 4.7%     | 5.1%     | 4.5%     |
| **Autism/ASDs**                 | 79.6%    | 65.9%    | 55.8%    | 41.1%    | 60.6%    |
| Chemical sensitivity            | 69.4%    | 68.3%    | 51.9%    | 23.2%    | 53.2%    |
| MCS                             | 81.6%    | 78.0%    | 63.5%    | 46.4%    | 67.4%    |
| Chemical sensitivity/MCS        | 83.7%    | 82.9%    | 84.6%    | 51.8%    | 75.8%    |
| Asthma/asthma-like conditions   | 81.6%    | 78.0%    | 71.2%    | 42.9%    | 68.4%    |

Table interpretation: for each condition (in italics), the first row indicates the prevalence in the general population, and rows below that indicate the co-prevalences. For instance, for chemical sensitivity for the US, the prevalence among the general population is 25.9% and, among these individuals, 42.9% also report diagnosed MCS.
proportions among the four countries are statistically different ($p < 0.03$, Chi-square test). However, among those with chemical sensitivity who also report fragrance sensitivity, the proportions are statistically similar ($p = 0.795$).

### Chemical sensitivity, asthma, and fragrance sensitivity

Across the countries, 26.0% of the general population report diagnosed asthma/asthma-like conditions (26.8%, 28.5%, 25.3%, 23.2%). In addition, 55.4% of individuals with chemical sensitivity also report asthma/asthma-like conditions (59.2%, 56.5%, 57.0%, 49.0%), and 42.6% of individuals with asthma/asthma-like conditions also report chemical sensitivity (57.0%, 37.4%, 36.7%, 39.2%). Further, 57.8% of individuals with asthma/asthma-like conditions are also fragrance sensitive (64.3%, 55.6%, 54.0%, 57.3%). Thus, individuals with chemical sensitivity are more likely to report asthma/asthma-like conditions, and individuals with asthma/asthma-like conditions are more likely to be chemically sensitive and fragrance sensitive, than the general population (Table 1). Among those with chemical sensitivity who also report asthma/asthma-like conditions, the proportions among the four countries are statistically similar ($p = 0.496$).

### Chemical sensitivity, autism, and fragrance sensitivity

Across the countries, 4.5% of the general population report diagnosed autism/ASDs (4.3%, 3.7%, 4.7%, 5.1%). In addition, 13.5% of individuals with chemical sensitivity also report autism/ASDs (13.3%, 13.0%, 16.2%, 11.3%), and 60.6% of individuals with autism/ASDs also report chemical sensitivity (79.6%, 65.9%, 55.8%, 41.1%). Further, 75.8% of individuals with autism/ASDs are also fragrance sensitive (83.7%, 82.9%, 84.6%, 51.8%). Thus, individuals with chemical sensitivity are more likely to report autism/ASDs, and individuals with autism/ASDs are more likely to be chemically sensitive.
and fragrance sensitive than the general population (Table 1). Among those with chemical sensitivity who also report autism/ASDs, the proportions among the four countries are statistically similar ($p = 0.624$).

**Chemical sensitivity and effects from fragranced products**

Fragranced products pose particular problems for the chemically sensitive. Results are summarized in this section and in Tables 2, 3, and 4. Full results for each country, according to the general population and sub-populations of those with chemical sensitivity, diagnosed MCS, and chemical sensitivity/MCS, are provided as Electronic supplementary material (ESM-Data).

Among chemically sensitive individuals, 82% are fragrance sensitive, reporting adverse health effects from fragranced consumer products. Fragranced products and exposure contexts that are associated with health problems include but are not limited to the following: air fresheners and deodorizers (54.8%), scented laundry products coming from a dryer vent (26.4%), being in a room recently cleaned with

| Table 4 Societal effects of fragranced consumer products |
|---------------------------------------------------------|
| Gen pop | ChemSens | MCS | ChemSens/MCS |
|---------------------------------------------------------|
| Fragrance sensitive | 32.2% | 82.0% | 89.2% | 81.3% |
| Disabling health effects from fragranced consumer products | 29.1% | 44.1% | 61.7% | 43.4% |
| Unable or reluctant to use restrooms in public place because of air freshener, deodorizer, or scented product | 13.3% | 37.4% | 54.6% | 37.3% |
| Unable or reluctant to wash hands in public place because of fragranced soap | 10.4% | 32.1% | 53.0% | 32.5% |
| Want to leave a business quickly because of fragranced product | 17.0% | 51.0% | 56.8% | 49.4% |
| Prevented from going someplace because of fragranced product that would cause sickness | 16.0% | 46.5% | 65.0% | 46.2% |
| Lost workdays or job in past year due to sickness from fragranced product exposure in workplace | 9.0% | 28.6% | 45.0% | 28.0% |
| Supportive of fragrance-free policy in the workplace | | | | |
| Yes | 47.8% | 70.2% | 69.9% | 69.5% |
| No | 20.4% | 10.9% | 19.7% | 11.7% |
| Prefer fragrance-free healthcare facilities and professionals | | | | |
| Yes | 51.4% | 75.4% | 76.5% | 74.4% |
| No | 22.1% | 11.9% | 15.3% | 12.8% |

| Table 5 Demographic information |
|--------------------------------|
| Gen pop | ChemSens | MCS | ChemSens/MCS |
|--------------------------------|
| Total (N) | 4435 | 884 | 329 | 943 |
| (% relative to general population) | 100.0% | 19.9% | 7.4% | 21.2% |
| Male/female | | | | |
| All males | 49.1% | 40.1% | 56.2% | 41.6% |
| All females | 51.0% | 59.9% | 43.8% | 58.4% |
| Gender and age | | | | |
| Male 18–24 | 6.5% | 5.4% | 11.1% | 6.4% |
| Male 25–34 | 10.2% | 11.7% | 19.6% | 12.2% |
| Male 35–44 | 11.2% | 9.7% | 14.8% | 10.1% |
| Male 45–54 | 10.9% | 7.7% | 5.4% | 7.5% |
| Male 55–65 | 10.3% | 5.6% | 5.3% | 5.5% |
| Female 18–24 | 7.1% | 8.1% | 6.1% | 8.0% |
| Female 25–34 | 11.5% | 12.8% | 10.9% | 12.4% |
| Female 35–44 | 12.2% | 14.7% | 8.5% | 14.2% |
| Female 45–54 | 11.3% | 13.6% | 11.7% | 13.4% |
| Female 55–65 | 9.0% | 10.7% | 6.7% | 10.4% |
scented products (53.8%), being near someone wearing a fragranced product (56.5%), and other types of fragranced consumer products (58.9%) (Table 2).

Types of adverse health effects associated with these fragranced product exposures, for chemically sensitive individuals, include respiratory symptoms (50.2%), mucosal symptoms (39.4%), migraine headaches (36.9%), skin problems (29.9%), asthma attacks (25.2%), and neurological problems (17.7%), among others (Table 3).

Disabling health problems can result from fragranced product exposures. The severity of health problems associated with fragranced products was investigated, using criteria from each country’s disability legislation (ADAAA 2008, DDA 1992, EA 2010, DA 2008). Among those adversely affected by fragranced products, for 29.1% of the general population, 44.1% of individuals with chemical sensitivity, and 61.7% of individuals with diagnosed MCS, the health effects from fragranced product exposures are reported as potentially disabling (Table 4, and ESM-Data Table 20).

Societal access can be restricted by fragranced products. For individuals with chemical sensitivity, 37.4% are unable or reluctant to use public restrooms that have an air freshener, deodorizer, or scented product; 32.1% are unable or reluctant to wash hands in a public place if the soap is fragranced; 51.0% enter a business but then leave as quickly as possible due to a fragranced product; and 46.5% have been prevented from going someplace because a fragranced product would make them sick (Table 4).

Lost workdays and lost jobs are associated with exposure to fragranced products: 9% of the general population, 28.6% of individuals with chemical sensitivity, and 45.0% of individuals with diagnosed MCS, have lost workdays or lost a job, in the past year, due to illness from fragranced product exposure in the workplace. For individuals with chemical sensitivity, this loss represents more than 23 million people in the four countries (Table 4 and ESM-Data Table 29; USCB 2018, ABS 2018, ONS 2018, SCB 2018). Among the general population, 47.8% would be supportive of a fragrance-free policy in the workplace (compared to 10.9% that would not). Also, 75.4% would prefer that healthcare facilities and healthcare professionals be fragrance-free (compared to 11.9% that would not). Thus, more than six times as many individuals with chemical sensitivity would prefer that workplaces, healthcare facilities, and healthcare professionals were fragrance-free than not (Table 4).

Fragrance-free policies receive strong support. Among those with chemical sensitivity, 70.2% would be supportive of a fragrance-free policy in the workplace (compared to 10.9% that would not). Also, 75.4% would prefer that healthcare facilities and healthcare professionals be fragrance-free (compared to 11.9% that would not). Thus, more than six times as many individuals with chemical sensitivity would prefer that workplaces, healthcare facilities, and healthcare professionals were fragrance-free than not (Table 4).

Among the general population, 47.8% would be supportive of a fragrance-free policy in the workplace (compared to 20.4% that would not). Also, 51.4% would prefer that healthcare facilities and healthcare professionals be fragrance-free (compared to 22.1% that would not). Thus, more than twice as many individuals in the general population would prefer that workplaces, healthcare facilities, and healthcare professionals were fragrance-free than not (Table 4).

Demographic proportions of chemical sensitivity are 40.1% male and 59.9% female, and diagnosed MCS are 56.2% male and 43.8% female, compared with the general population proportions of 49.1% male and 51.0% female. Thus, chemical sensitivity has a female bias (+ 8.9%), and diagnosed MCS has a male bias (+ 7.1%). Relative to gender and age, the highest bias for chemical sensitivity is female 35–44 (+ 2.5%) and for diagnosed MCS is male 25–34 (+ 9.4%) (Table 5).

Discussion and conclusion

Chemical sensitivity is pervasive across the four countries, affecting an estimated 61 million adults (USCB 2018, ABS 2018, ONS 2018, SCB 2018). Individuals with chemical sensitivity, asthma/asthma-like conditions, and autism/ASDs all have a higher prevalence of fragrance sensitivity than those without these conditions.

Chemically sensitive individuals are proportionally more likely to report asthma/asthma-like conditions (POR 5.54; 95% CI 4.74–6.49), autism/ASDs (POR 6.68; 95% CI 4.98–8.97), and fragrance sensitivity (POR 18.54; 95% CI 15.32–22.43) than non-chemically sensitive individuals.

Also, individuals with asthma/asthma-like conditions are proportionally more likely to report chemical sensitivity (POR 5.54; 95% CI 2.23–3.99) and fragrance sensitivity (POR 4.54; 95% CI 3.93–5.23) than individuals without asthma/asthma-like conditions. In addition, individuals with autism/ASDs are proportionally more likely to report chemical sensitivity (POR 7.55; 95% CI 5.57–10.24) and fragrance sensitivity (POR 7.25; 95% CI 5.21–10.10) than individuals without autism/ASDs.

Even though the prevalences of each chemical sensitivity, diagnosed MCS, and fragrance sensitivity among the four countries are statistically different, the co-prevalences of conditions are statistically similar for chemical sensitivity with fragrance sensitivity, chemical sensitivity with asthma/asthma-like conditions, and chemical sensitivity with autism/ASDs.

Further, the proportion of individuals with diagnosed MCS who also report chemical sensitivity is statistically similar across the countries. However, the proportion of individuals with chemical sensitivity who also report diagnosed MCS is statistically different across the countries.

Study strengths include the following: (a) sample populations are statistically representative of the general populations according to age, gender, and region in each country; (b) survey respondents were randomly recruited from large web-based panels that reflect population characteristics; and (c)
the survey replicated questions from previous national population studies for consistency and comparability. Study limitations include the following: (a) only adults ages 18–65 were surveyed, which excludes data from other age groups; (b) the survey relied on self-reported data, although self-report is a standard and widely accepted approach for epidemiological research; and (c) the cross-sectional design of the survey obtains data from one point in time, although the survey can be repeated.

In conclusion, the study indicates that chemical sensitivity is an international public health problem. Further, individuals with chemical sensitivity report a higher co-prevalence of fragrance sensitivity, asthma/asthma-like conditions, and autism/ASDs than individuals without chemical sensitivity. Exposure to fragranced consumer products can exacerbate the adverse health and societal effects, especially for these vulnerable subpopulations with chemical sensitivity, asthma/asthma-like conditions, and autism/ASDs. Reducing exposure to fragranced products, such as through fragrance-free policies, can reduce adverse effects for not only vulnerable individuals but also the general population.

Acknowledgements I thank the anonymous reviewers of this article for their very helpful comments. I also thank John Barrie and Survey Sampling International for their valuable contributions. This article is written as a tribute to my departed colleague, Dr. Stanley Caress.

Funding The survey research in Australia was supported in part by the Australian Government’s National Environmental Science Program through the Clean Air and Urban Landscapes Hub.

Compliance with ethical standards

The research study received ethics approval from the University of Melbourne.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

Americans with Disabilities Act Amendments Act of 2008 (ADAAA) (2008) 42 U.S. Code § 12102—definition of disability (Pub. L. 101–336, § 3, July 26, 1990, 104 Stat. 329; Pub. L. 112–25, § 4(a), Sept. 25, 2008, 122 Stat. 3555.) Available at: https://www.law.cornell.edu/uscode/text/42/12102 Accessed 26 Jan 2019

Ashford NA, Miller CS (1998) Chemical exposures: low levels and high stakes, 2nd edn. John Wiley and Sons, Inc, New York, N.Y

Australian Bureau of Statistics (ABS) (2018) Census data for Australia (estimated 2016 population of adults ages 18–65 is 14,507,551). http://www.censusdata.abs.gov.au/census_services/getproduct/census/2016/quickstat/036/openDocument Accessed 26 Jan 2019

Azuma K, Uchiyama I, Katoh T, Ogata H, Arashidani K, Kunugita N (2015) Prevalence and characteristics of chemical intolerance: a Japanese population-based study. Arch Environ Occup Health 70:341–353

Berg ND, Linneberg A, Dirksen A, Elberling J (2008) Prevalence of self-reported symptoms and consequences related to inhalation of airborne chemicals in a Danish general population. Int Arch Occup Environ Health 81:881–887

Caress S, Steinemann A (2003) A review of a two-phase population study of multiple chemical sensitivities. Environ Health Perspect 111(12):1490–1497

Caress S, Steinemann A (2005) National Prevalence of asthma and chemical hypersensitivity: an examination of potential overlap. J Occup Environ Med 47(5):518–522

Caress SM, Steinemann AC (2009a) Asthma and chemical hypersensitivity: prevalence, etiology, and age of onset. Toxicol Ind Health 25(1):71–78

Caress SM, Steinemann AC (2009b) Prevalence of fragrance sensitivity in the American population. J Environ Health 71(7):46–50

De Luca C, Raskovic D, Pacifico V, Thai JCS, Korkina L (2011) The search for reliable biomarkers of disease in multiple chemical sensitivity and other environmental intolerances. Int J Environ Res Public Health 8(7):2770–2797

Disability Discrimination Act (DDA) (1992) Australian government. Act no. 135 of 1992, https://www.legislation.gov.uk/ukpga/1992/135/pdfs/ukpga_1992_135_en.pdf Accessed 26 Jan 2019

Disability Discrimination Act (Diskrimineringslagen) (DA) (2008) SFS No: 2008:567, Section 5:4. Definition of disability https://www.rksdagen.se/sv/dokument-lagar/dokument/svensk-forfattningssamling/diskrimineringslag-2008567_sfs-2008-567, https://www.government.se/contentassets/6732121a2eb54ec3b21da9c628b6bd6c7/oversattningsdiskrimineringslagen_eng.pdf Accessed 26 Jan 2019

Equality Act (EA) (2010) Chapter 15. Parliament of the United Kingdom. https://www.legislation.gov.uk/ukpga/2010/15/pdfs/ukpga_20100015_en.pdf Accessed 26 Jan 2019

Eysenbach G (2004) Improving the quality of web surveys: the checklist for reporting results of internet E-surveys (CHERRIES). J Med Internet Res 6(3):e34

Genuis SJ (2010) Sensitivity-related illness: the escalating pandemic of allergy, food intolerance and chemical sensitivity. Sci Total Environ 408(24):6047–6061

Kreutzer R, Neutra RR, Lashuay N (1999) Prevalence of people reporting sensitivities to chemicals in a population-based survey. Am J Epidemiol 150(1):1–12

Lacour M, Zunder T, Schmidtke K, Vaiht P, Scheidt C (2005) Multiple chemical sensitivity syndrome (MCS)—suggestions for an extension of the U.S. MCS-case definition. Int J Hyg Environ Health 208(3):141–151

McDonald BC, de Gouw JA, Gilman JB, Jathar SH, Akherati A, Cappa CD et al (2018) Volatile chemical products emerging as largest petrochemical source of urban organic emissions. Science 359(6377):760–764

MCS (1999) Multiple chemical sensitivity: a 1999 consensus. Arch Environ Health 54(3):147–149

Miller CS (1997) Toxicant-induced loss of tolerance—an emerging theory of disease? Environ Health Perspect 105(Suppl 2):445–453

Miller CS (2001) The compelling anomaly of chemical intolerance. Ann N Y Acad Sci 933:1–23

Miller CS, Prihoda TJ (1999) The environmental exposure and sensitivity inventory (ESEI): a standardized approach for measuring chemical intolerances for research and clinical applications. Toxicol Ind Health 15(3–4):370–385
Office for National Statistics, United Kingdom (ONS) (2018) Population estimates. Analysis tool. (Estimated 2016 population of adults ages 18–65 is 35,395,854.) https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates Accessed 26 Jan 2019

Ott W, Steinemann A, Wallace L (eds) (2007) Exposure analysis. CRC Press, Boca Raton, FL

Palmquist E, Claesson AS, Neely G, Stenberg B, Nordin S (2014) Overlap in prevalence between various types of environmental intolerance. Int J Hyg Environ Health 217(4–5):427–434

Sell C (ed) (2006) The chemistry of fragrances: from perfume to consumer. 2nd edn. The Royal Society of Chemistry, Cambridge

Skovbjerg S, Berg ND, Elberling J, Christensen KB 2012. Evaluation of the quick environmental exposure and sensitivity inventory in a Danish population, 1–10

SSI (Survey Sampling International) 2016. Dynamix sampling approach. Available from: https://www.surveysampling.com/technology/ssi-dynamix/ Accessed 26 Jan 2019

Statistics Sweden, Statistiska centralbyrån (SCB) (2018) Sweden Government Offices. (Estimated 2017 population of adults ages 18–65 is 5,992,498) http://www.scb.se/en/finding-statistics/statistics-by-subject-area/population/population-composition/population-statistics/pong/tables-and-graphs/yearly-statistics%2D%2Dthe-whole-country/summary-of-population-statistics/ Accessed 26 Jan 2019

Steinemann A (2015) Volatile emissions from common consumer products. Air Qual Atmos Health 8(3):273–281

Steinemann A (2016) Fragranced consumer products: exposures and effects from emissions. Air Qual Atmos Health 9(8):861–866

Steinemann A (2017) Health and societal effects from fragranced consumer products. Prevent Med Rep 5:45–47

Steinemann A (2018a) Fragranced consumer products: sources of emissions, exposures, and health effects in the United Kingdom. Air Qual Atmos Health 11(3):253–258

Steinemann A (2018b) Exposures and effects from fragranced consumer products in Sweden. Air Qual Atmos Health 11(5):485–491

Steinemann A (2018c) National Prevalence and effects of multiple chemical sensitivities. J Occup Environ Med 60(3):e152–e156

Steinemann A (2018d) Prevalence and effects of multiple chemical sensitivities in Australia. Prevent Med Rep 10:191–194

Steinemann A (2018e) Fragranced consumer products: Effects on autistic adults in the United States, Australia, and United Kingdom. Air Quality, Atmosphere, and Health, Sept: 1–6

Steinemann A (2018f) Chemical sensitivity, asthma, and effects from fragranced consumer products: National population study in Sweden. Air Quality, Atmosphere, and Health (online 1 Nov)

Steinemann A (2018g) Fragranced consumer products: effects on asthmatics. Air Qual Atmos Health 11(1):3–9

Steinemann A (2019) Chemical sensitivity, asthma, and effects from fragranced consumer products: National population study in the United Kingdom. Air Quality, Atmosphere and Health. (online 02 Jan)

Steinemann A, Wheeler AJ, Larcombe A (2018) Fragranced consumer products: effects on asthmatic Australians. Air Qual Atmos Health 11(4):365–371

United States Census Bureau (USCB) (2018) Quick facts. Population; age and sex. (Estimated 2016 population of adults ages 18–65 is 199,864,867) Available at: https://www.census.gov/quickfacts/fact/table/US/AGE275210#viewtop Accessed 26 Jan 2019

Weinberg JL, Flattery J, Harrison R (2017) Fragrances and work-related asthma–California surveillance data, 1993–2012. J Asthma:1–10